Filtered By:
Cancer: Chronic Lymphocytic Leukemia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 25 results found since Jan 2013.

Viruses, Vol. 15, Pages 1235: Ischaemic Stroke Occurring in a Patient Treated with Monoclonal Antibodies for COVID-19
In conclusion, among several side effects that have been described during the treatment of COVID-19 with sotrovimab, ischaemic stroke was not reported. Therefore, we here report a rare case of ischaemic stroke with early clinical manifestation after the administration of sotrovimab for the treatment of moderate COVID-19 in an immunocompromised patient for the first time.
Source: Viruses - May 25, 2023 Category: Virology Authors: Antonio Lobasso Ciro di Gennaro Maria Rita Poggiano Antonio Vasta Raffaele Angelo Nicola Ranucci Roberto Lobianco Anna Giacoma Tucci Enrico Cavagli à Pierpaolo Di Micco Tags: Case Report Source Type: research

Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
CONCLUSION: This study highlights that elevated baseline AF/stroke-related risk does not adversely impact TTD and TTNT outcomes associated with ibrutinib use. Additionally, TTNT was significantly longer for patients treated with ibrutinib vs. other regimens.PMID:35973891 | DOI:10.1016/j.clml.2022.07.004
Source: Clinical Lymphoma and Myeloma - August 16, 2022 Category: Cancer & Oncology Authors: Anna Narezkina Nausheen Akhter Xiaoxiao Lu Bruno Emond Sumeet Panjabi Shaun P Forbes Annalise Hilts Stephanie Liu Marie-H élène Lafeuille Patrick Lefebvre Qing Huang Michael Choi Source Type: research

Listeria monocytogenes Meningoencephalitis Mimicking Stroke in a Patient with Chronic Lymphocytic Leukemia
Conclusion The supratentorial focal lesions secondary to Listeria meningoencephalitis are rare. The cases with focal neurological signs without fever at onset can resemble stroke.
Source: Neurology and Therapy - December 1, 2013 Category: Neurology Source Type: research

Real-World Persistence and Time to Next Treatment with Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
: Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF/stroke risk remain unknown.
Source: Clinical Lymphoma, Myeloma and Leukemia - July 12, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Sumeet Panjabi, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-H élène Lafeuille, Patrick Lefebvre, Qing Huang, Michael Choi Tags: Original Study Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database
CONCLUSION: CLL patients with AF are at a significantly increased risk of all-cause mortality, cardiac-related mortality, and stroke. For this population, a multidisciplinary approach should be orchestrated for better management and outcomes.PMID:34598909 | DOI:10.1016/j.clml.2021.08.006
Source: Clinical Lymphoma and Myeloma - October 2, 2021 Category: Cancer & Oncology Authors: Mohammad Ammad Ud Din Samarthkumar Thakkar Harsh Patel Hassan Saeed Syed Ather Hussain Hania Liaqat Aneeqa Zafar Sourbha S Dani Sarju Ganatra Faiz Anwer Source Type: research

An unusual cause of cerebellar ataxia in an immunocompromised elderly patient
Conclusions: PVB19 CNS infection should be in the differential as a cause of cerebellar ataxia in immunocompromised patients. Recognition is critical to early institution of appropriate therapy. Our patient showed considerable improvement in ataxia after IVIG therapy.Highlights:
Source: Journal of the Neurological Sciences - March 13, 2014 Category: Neurology Authors: Sheetal Shroff, Carlos Kamiya-Matsuoka, Karin Woodman Tags: Short Communications Source Type: research

Abstract 5267: Comorbidity and cause of death in patients with chronic lymphocytic leukemia (CLL)
Conclusions. Despite the advanced age at CLL diagnosis, the frequent presence of comorbidities, and the indolent nature of the disease, CLL progression is the ultimate cause of death in 51% of newly diagnosed CLL patients, with an additional 26% dying of causes potentially related to CLL, such as infections and second cancers. The influence of comorbidities and other clinical factors at diagnosis (e.g. smoking, Charlson Comorbidity Index) on survival and ultimate cause of death are being abstracted, and will be presented at the meeting.Citation Format: Paolo Strati, Kari Chaffe, Sara Achenbach, Timothy Call, Neil Kay, Jame...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Strati, P., Chaffe, K., Achenbach, S., Call, T., Kay, N., Cerhan, J., Slager, S., Shanafelt, T. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research

Daily low-dose aspirin may help combat cancer
Conclusion The systematic review looked at 47 studies and attempted to combine the results, looking for evidence of a beneficial effect of low-dose aspirin on risk of death in people already diagnosed with cancer. The few RCTs identified – the best-quality evidence – did not provide conclusive evidence that aspirin improves survival rates. The rest of the studies were observational in nature, so cannot prove that aspirin reduces the risk of death from cancer. The only significant results were for a 24% reduction in risk of death from colon cancer, and a possible 11% reduced risk of death from prostate cancer. However,...
Source: NHS News Feed - April 22, 2016 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Stephen P. Mulligan, Christopher M. Ward, David Whalley, Sarah N. Hilmer Tags: Editorial Comment Source Type: research

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Summary Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non‐thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%)....
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Philip A. Thompson, Vincent L évy, Constantine S. Tam, Chadi Al Nawakil, François‐Xavier Goudot, Anne Quinquenel, Loic Ysebaert, Anne‐Sophie Michallet, Marie‐Sarah Dilhuydy, Eric Van Den Neste, Jehan Dupuis, Michael J. Keating, Christophe Meune, F Tags: Short Report Source Type: research